Elucid to Showcase PlaqueIQ™ at SCCT 2025
PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. The software is designed to help physicians prioritize and personalize treatment based on actual disease.
Share
Elucid CEO Kelly Huang, PhD, will participate in the Novel Technologies keynote session, which will be held on Friday, July 18 from 5:05 to 6:15 p.m. ET in room 210 B/F. Kelly's presentation, 'Lesion, vessel, patient, population. Anatomy, physiology, morphology: A complete picture,' will detail the importance of plaque morphology quantification and classification at the lesion level and why morphology based on histology is the gold standard for plaque characterization.
Elucid will also host a breakfast symposium, ' From Lesion Detail to the Patient: Getting the Entire Story with Anatomy, Physiology and Morphology,' Friday, July 18 from 7 to 7:50 a.m. ET in room 511 C/F. The session will feature two of the preeminent experts in preventative cardiology and CCTA-derived plaque morphology: Dr. Amir Ahmadi, associate professor of medicine and cardiology director, Inpatient Cardiology at Mount Sinai Fuster Heart at Morningside and Elucid lead scientific advisor, and Dr. Mark D. Berlacher, clinical cardiologist at The Christ Hospital. The session will provide a deep dive into several plaque cases using Elucid's software and share how these findings influence treatment pathways. The program will also explore FFR CT features on an investigational basis. 1
'The cases we will present at SCCT 2025 demonstrate the importance of moving beyond the vessel level to assess plaque at the lesion level,' said Dr. Berlacher. 'Having detailed information about the amount and type of plaque at the lesion level, including lipid rich necrotic core, can help drive treatment decisions and help physicians get ahead of potentially deadly cardiac events.'
In addition to its participation in the SCCT 2025 program, Elucid will hold three dinner presentations and discussions on Thursday, July 17, Friday, July 18, and Saturday, July 19. The presentation, 'CT-Guided Treatment of Coronary Artery Disease: A Step Toward Precision Medicine,' features Dr. Ahmadi, and will also include product demos.
Attendees may also participate in hands-on demos of Elucid's flagship PlaqueIQ image analysis software, as well as its FFR CT plaque-based algorithm (in development), in Booth 215 during exhibit hall hours. Additionally, Amy Pyke, Elucid's senior vice president of Market Access, will host reimbursement Q&A office hours in the booth on Friday from 11:30 a.m. to 12:30 p.m. ET and Saturday from 12:30 to 1:30 p.m. ET.
PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk.
About Elucid
Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ™ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit elucid.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
5 minutes ago
- The Hill
Sam's Club freeze dried fruit recalled over possible Listeria contamination
A recall has been issued for a popular dried fruit snack sold at Sam's Club amid concerns that the packages may be contaminated with Listeria. The snack is Member's Mark Freeze Dried Fruit Variety Pack 15-count. The U.S. Food and Drug Administration announced the recall by Doehler Dry Ingredient Solutions LLC, in a press release Thursday, noting that no illnesses had been reported yet from the possible Listeria monocytogenes exposure. According to the Food and Drug Administration (FDA), the contamination was discovered by the company during 'internal testing of their products.' The potentially affected products were distributed between July 1-25 and were sold at Sam's Club stores across the U.S. The FDA is advising people not to consume the snack if they purchased it during that window of time. Listeria monocytogenes can cause serious and sometimes fatal infections in young children, elderly people, and those with weakened immune systems. Exposure among healthy people can lead to symptoms like fevers, nausea and abdominal pain. Health officials warn that listeria can result in miscarriages and stillbirths among pregnant women.
Business Wire
24 minutes ago
- Business Wire
KBRA Assigns Preliminary Ratings to VRTX 2025-HQ
NEW YORK--(BUSINESS WIRE)--KBRA announces the assignment of preliminary ratings to five classes of VRTX 2025-HQ, a CMBS single-borrower securitization. The collateral for the transaction is a $600 million portion of a $1.0 billion fixed rate, interest-only first lien mortgage loan. The fixed-rate loan has a five-year term and requires monthly interest-only payments based on an assumed interest rate of 6.25%. The loan is secured by the borrower's fee simple interest in Vertex HQ , two 15-story, Class-A, LEED Gold office tower containing 1.1 million sf. The building is located in the Seaport neighborhood of downtown Boston. The buildings were developed in 2013 as a built-to-suit corporate headquarters for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). KBRA performed a credit estimate on Vertex, and the results of the analysis indicated that Vertex has credit characteristics consistent with an entity with an investment grade rating. Vertex leases all of the office and lab space at the property and represents 96.8% of base rent. The tenant recently renewed its lease through 2044, or approximately 14 years beyond the loan term. KBRA's analysis of the transaction included a detailed evaluation of the property's cash flows using our North American CMBS Property Evaluation Methodology and the application of our North American CMBS Single Borrower & Large Loan Rating Methodology. In addition, KBRA also relied on its Global Structured Finance Counterparty Methodology for assessing counterparty risk in this transaction, and its ESG Global Rating Methodology, to the extent deemed applicable. The results of our analysis yielded a KBRA net cash flow (KNCF) for the subject of approximately $87.6 million, which is 4.7% below the issuer's NCF, and a KBRA value of $1.06 billion, which is 34.7% below the appraiser's value. The resulting in-trust KBRA Loan to Value (KLTV) is 94.2%. In our analysis of the transaction, we also reviewed and considered third party engineering, environmental, and appraisal reports, the results of our site inspection of the property, and legal documentation review. To access ratings and relevant documents, click here. Click here to view the report. Methodologies Disclosures Further information on key credit considerations, sensitivity analyses that consider what factors can affect these credit ratings and how they could lead to an upgrade or a downgrade, and ESG factors (where they are a key driver behind the change to the credit rating or rating outlook) can be found in the full rating report referenced above. A description of all substantially material sources that were used to prepare the credit rating and information on the methodology(ies) (inclusive of any material models and sensitivity analyses of the relevant key rating assumptions, as applicable) used in determining the credit rating is available in the Information Disclosure Form(s) located here. Information on the meaning of each rating category can be located here. Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above. Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at About KBRA Kroll Bond Rating Agency, LLC (KBRA), one of the major credit rating agencies (CRA), is a full-service CRA registered with the U.S. Securities and Exchange Commission as an NRSRO. Kroll Bond Rating Agency Europe Limited is registered as a CRA with the European Securities and Markets Authority. Kroll Bond Rating Agency UK Limited is registered as a CRA with the UK Financial Conduct Authority. In addition, KBRA is designated as a Designated Rating Organization (DRO) by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized as a Qualified Rating Agency by Taiwan's Financial Supervisory Commission and is recognized by the National Association of Insurance Commissioners as a Credit Rating Provider (CRP) in the U.S. Doc ID: 1010618
Yahoo
25 minutes ago
- Yahoo
Nintendo is raising prices on the original Switch game consoles due to 'market conditions'
Being a Nintendo fan keeps getting more expensive. Nintendo's latest price hikes impact the original Nintendo Switch and some Switch 2 accessories. Tariff-related costs are the likely culprit — with Nintendo citing "market conditions." Mario is asking for more gold coins. Nintendo is raising prices on the original Nintendo Switch game consoles, along with some Switch 2 accessories. "Pricing for the original Nintendo Switch™ family of systems and products will change in the United States based on market conditions, effective August 3, 2025," the company said. "These include Nintendo Switch — OLED Model, Nintendo Switch, Nintendo Switch Lite and select Nintendo Switch accessories." It's not yet clear what the new prices will be. The original Nintendo Switch was listed at $299.99, while the OLED model with an improved screen sold for $349.99. "Other Nintendo products, including certain Nintendo Switch 2 accessories, select amiibo, and the Nintendo Sound Clock: Alarmo, will also see adjustments," the company said. The company is not raising the price of its more expensive Switch 2, though it said it's not ruling out a future price hike, saying that "price adjustments may be necessary in the future." Nintendo previously delayed pre-orders of the Nintendo Switch 2 amid tariff uncertainty before deciding not to raise the price of the game console itself — instead boosting the price of Switch 2 accessories. Nintendo's mention of "market conditions" is a likely reference to President Donald Trump's tariffs, which continue to evolve. The company previously moved some production of its original Switch from China to Vietnam due to economic tensions between China and the US. On Thursday, Trump announced changes to his planned "reciprocal" tariffs, with Vietnam now facing a 20% rate. Read the original article on Business Insider
